Alzheimer's Disease
Filter News
Found 1,100 articles
-
The FDA plans to convene an advisory committee meeting to discuss the safety profile and efficacy of Eli Lilly’s Alzheimer’s candidate, the company announced Friday.
-
The regulator’s new draft guidance, released on Monday, provides additional details regarding the use of surrogate and biomarker endpoints to support accelerated approvals.
-
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
3/12/2024
IGC Pharma, Inc. announced that it has appointed Terry Lierman as an independent director to its board of directors.
-
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
3/11/2024
BioVie Inc. today announced that its recently completed funding round provides opportunity to further the Company’s clinical priorities in Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and ascites/liver disease.
-
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
3/11/2024
Allyx Therapeutics announced that its lead compound, ALX-001, is ready to proceed to Phase 2 clinical development in Alzheimer’s and Parkinson’s disease.
-
Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease
3/11/2024
Cognito Therapeutics announced today results from the OVERTURE open label extension (OLE) study presented in an oral session at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson's Disease.
-
The FDA will convene its Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly’s application for its Alzheimer’s disease antibody donanemab, the company announced Friday.
-
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’sAgency to convene an advisory committee to consider the drug
3/8/2024
The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the drug’s safety and efficacy, further delaying approval of the promising drug.
-
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
3/8/2024
Acumen Pharmaceuticals, Inc. today presented cerebrospinal fluid (CSF) biomarker data from the sabirnetug (ACU193) Phase 1 INTERCEPT-AD trial in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Lisbon, Portugal, and online.
-
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference
3/7/2024
AlzeCure Pharma announced that the company's presentation at the Alzheimer's conference AD/PD 2024, regarding new preclinical data with its leading clinical drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease, is now available on the company's website.
-
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference
3/7/2024
CuraSen Therapeutics, Inc. announced that it will present additional positive Phase 2a data with its combination adrenergic activator, CST-2032/CST-107.
-
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
3/6/2024
Cognition Therapeutics, Inc. is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal).
-
Varoglutamstat, a drug developed by German biotech Vivoryon Therapeutcs, did not hit its primary and secondary endpoints in a Phase IIb study in Alzheimer’s disease.
-
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
3/5/2024
Tiziana Life Sciences Ltd., a biotechnology company developing breakthrough neuro-immunomodulation therapies, announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer’s and Parkinson’s disease at AD/PD, March 5-9, 2024.
-
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
3/5/2024
INmune Bio, Inc., a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease reports significant improvements in electroencephalography, a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
-
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/5/2024
Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease in the U.S.
-
New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood
3/5/2024
Sunbird Bio today announced new data demonstrating that their APEX (Amplified Plasmonic EXosomes) amyloid beta (Aβ) test, the company’s investigational blood-based diagnostic in Alzheimer’s disease, effectively discriminated between patients who were positive versus negative for Aβ on positron emission tomography (PET) scans.
-
AlzeCure Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's
3/5/2024
AlzeCure Pharma AB announced that another scientific article has been published on the phase I clinical results supporting the continued development of the lead drug candidate NeuroRestore ACD856.
-
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
3/4/2024
Quanterix Corporation announced today that its Simoa ® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD).
-
Neurocode Launches Groundbreaking pTau217 Blood Test for Alzheimer's Disease Clinical Diagnosis
3/4/2024
Neurocode USA , Inc is pleased to announce the clinical launch of ALZpath Dx, an innovative and novel blood test that can be used in the screening, diagnosis, and monitoring of Alzheimer's disease (AD) based on circulating level of pTau217 in the blood.